Impact of Tissue Plasminogen Activator on the Neurovascular Unit: From Clinical Data to Experimental Evidence

Outcomes of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 90 Years or Older

(2012) Farrah J. Mateen et al.   MAYO CLINIC PROCEEDINGS

The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke

(2012) Peter Sandercock et al.   Trials

Platelet Protease Nexin-1, a Serpin That Strongly Influences Fibrinolysis and Thrombolysis

(2011) Yacine Boulaftali et al.   CIRCULATION

Tissue plasminogen activator prevents white matter damage following stroke

(2011) Fernando Correa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Stroke and the immune system: from pathophysiology to new therapeutic strategies

(2011) Richard Macrez et al.   LANCET NEUROLOGY

Enriched housing reverses age-associated impairment of cognitive functions and tPA-dependent maturation of BDNF

(2011) Pauline Obiang et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Population-based study of wake-up strokes

(2011) J. Mackey et al.   NEUROLOGY

Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- d -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis

(2011) Richard Macrez et al.   STROKE

Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke

(2010) Shyam Prabhakaran   ARCHIVES OF NEUROLOGY

Association of Admission Blood Glucose and Outcome in Patients Treated With Intravenous Thrombolysis

(2010) Niaz Ahmed   ARCHIVES OF NEUROLOGY

Hypothermia for Stroke: Call to Action 2010

(2010) Malcolm R. Macleod et al.   International Journal of Stroke

Annexin A2 Combined with Low-Dose tPA Improves Thrombolytic Therapy in a Rat Model of Focal Embolic Stroke

(2010) Haihao Zhu et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

(2010) Kennedy R Lees et al.   LANCET

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke

(2010) Mar Hernandez-Guillamon et al.   STROKE

Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke

(2010) Rohit Bhatia et al.   STROKE

Safety and Efficacy of Ultrasound-Enhanced Thrombolysis

(2010) Georgios Tsivgoulis et al.   STROKE

Graphic Reanalysis of the Two NINDS-tPA Trials Confirms Substantial Treatment Benefit

(2010) Jeffrey L. Saver et al.   STROKE

Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke Onset

(2010) Jennifer Diedler et al.   STROKE

Intravenous Alteplase for Stroke in Those Older Than 80 Years Old

(2010) Gary A. Ford et al.   STROKE

Efficacy of Intra-Arterial Fibrinolysis for Acute Ischemic Stroke

(2010) Meng Lee et al.   STROKE

Functional Occurrence of the Interaction of Tissue Plasminogen Activator With the NR1 Subunit of N -Methyl- d -Aspartate Receptors During Stroke

(2010) Richard Macrez et al.   STROKE

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L)

(2010) Thomas M. Hemmen et al.   STROKE

A Mouse Model of Hemorrhagic Transformation by Delayed Tissue Plasminogen Activator Administration After In Situ Thromboembolic Stroke

(2010) Isaac García-Yébenes et al.   STROKE

A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial

(2010) SM Zinkstok et al.   Trials

Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein

(2009) Y. Suzuki et al.   BLOOD

Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact

(2009) Benoit D. Roussel et al.   BRAIN

NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity

(2009) A Baron et al.   CELL DEATH AND DIFFERENTIATION

Intravenous Thrombolysis with Rt-Pa in Acute Stroke Patients Aged ≥ 80 Years

(2009) Danilo Toni et al.   International Journal of Stroke

Microglial Low-Density Lipoprotein Receptor-Related Protein 1 Mediates the Effect of Tissue-Type Plasminogen Activator on Matrix Metalloproteinase-9 Activity in the Ischemic Brain

(2009) Chen Zhang et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Rosiglitazone Alone Or in Combination with Tissue Plasminogen Activator Improves Ischemic Brain Injury in an Embolic Model in Rats

(2009) Chen Xu Wang et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Combination Therapy of 17 -Estradiol and Recombinant Tissue Plasminogen Activator for Experimental Ischemic Stroke

(2009) R. Liu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Penumbral selection of patients for trials of acute stroke therapy

(2009) Geoffrey A Donnan et al.   LANCET NEUROLOGY

Comparison of intravenous alteplase with a combined intravenous–endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study

(2009) Mikael Mazighi et al.   LANCET NEUROLOGY

Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial

(2009) Erich Bluhmki et al.   LANCET NEUROLOGY

Good clinical outcome after ischemic stroke with successful revascularization is time-dependent

(2009) P. Khatri et al.   NEUROLOGY

Predictors of Good Clinical Outcomes, Mortality, and Successful Revascularization in Patients With Acute Ischemic Stroke Undergoing Thrombectomy

(2009) Raul G. Nogueira et al.   STROKE

Thrombolytic Therapy for Patients Who Wake-Up With Stroke

(2009) Andrew D. Barreto et al.   STROKE

Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke

(2009) Maarten G. Lansberg et al.   STROKE

Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis

(2009) Niaz Ahmed et al.   STROKE

Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator

(2009) Gregory J. del Zoppo et al.   STROKE

Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke

(2009) Brett Cucchiara et al.   STROKE

Revascularization Results in the Interventional Management of Stroke II Trial

(2008) T. Tomsick et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Regulated Intramembrane Proteolysis of the Low-Density Lipoprotein Receptor-Related Protein Mediates Ischemic Cell Death

(2008) Rohini Polavarapu et al.   AMERICAN JOURNAL OF PATHOLOGY

Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury

(2008) Chen Xu Wang et al.   EXPERIMENTAL NEUROLOGY

Methodology of the Interventional Management of Stroke III Trial

(2008) Pooja Khatri et al.   International Journal of Stroke

Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity

(2008) Jose P Lopez-Atalaya et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update

(2008) L Derex et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study

(2008) Nils Wahlgren et al.   LANCET

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

(2008) Stephen M Davis et al.   LANCET NEUROLOGY

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

(2008) Enming J Su et al.   NATURE MEDICINE

Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008

(2008) P. Ringleb et al.   NERVENARZT

Differential Regulation of Matrix Metalloproteinase-9 and Tissue Plasminogen Activator Activity by the Cyclic-AMP System in Lipopolysaccharide-stimulated Rat Primary Astrocytes

(2008) Soon Young Lee et al.   NEUROCHEMICAL RESEARCH

Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: A multicenter study

(2008) M. Saqqur et al.   NEUROLOGY

Thrombolytic Therapy for Acute Stroke — Not a Moment to Lose

(2008) Patrick Lyden   NEW ENGLAND JOURNAL OF MEDICINE

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic Effect of an Endothelin Type A Receptor Antagonist, S-0139, With rtPA on the Neuroprotection After Embolic Stroke

(2008) Rui Lan Zhang et al.   STROKE

Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke

(2008) Yoshihiro Murata et al.   STROKE

The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke

(2008) Arthur M. Pancioli et al.   STROKE

Treating Patients With ‘Wake-Up’ Stroke

(2008) Harold P. Adams et al.   STROKE

Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic

(2008) Manuel Yepes et al.   TRENDS IN NEUROSCIENCES